发明名称 |
Multiple-variable dose regimen for treating TNFα-related disorders |
摘要 |
Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase. |
申请公布号 |
US8961973(B2) |
申请公布日期 |
2015.02.24 |
申请号 |
US201414229664 |
申请日期 |
2014.03.28 |
申请人 |
AbbVie Biotechnology Ltd. |
发明人 |
Hoffman Rebecca S.;Chartash Elliot Keith;Taylor Lori K.;Granneman George Richard;Yan Philip |
分类号 |
A61K39/395;C07K16/24;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
Ropes & Gray LLP |
代理人 |
Ropes & Gray LLP ;Mangasarian Karen;Li Qianru |
主权项 |
1. A multiple-variable dose method for inducing clinical remission of Crohn's disease in a subject in need thereof, comprising subcutaneously administering to the subject:
a first dose of 160 mg of a recombinant human anti-TNFα antibody administered to the subject within a day; and a second dose of 80 mg of the antibody administered to the subject within a day, wherein the second dose is administered two weeks following administration of the first dose; wherein the antibody comprises:
a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:8; a CDR2 comprising the amino acid sequence of SEQ ID NO:6; and a CDR3 comprising the amino acid sequence of SEQ ID NO:4; anda light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:7; a CDR2 comprising the amino acid sequence of SEQ ID NO:5; and a CDR3 comprising the amino acid sequence of SEQ ID NO:3. |
地址 |
Hamilton BM |